Rimegepant safety and patient-reported outcomes among triptan-naïve, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study
Cephalalgia · 2025
DOI: 10.1177/03331024251343309 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cephalalgia, 2025. Verfasst von Jessica Ailani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Georgetown Headache Center, Medstar Georgetown University Hospital, Washington, DC, USA. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders, Patient Reported Outcome Measures, Piperidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Rimegepant was safe and well tolerated in a multicenter, open-label, phase 2/3 trial for acute treatment of migraine administered as 75 mg every other day (EOD) and as needed (PRN; EOD + PRN) for 12 weeks or PRN for 52 weeks.
Methods
Post-hoc analysis of this long-term safety study in adults was conducted according to five subgroups based on current and historical triptan use: current triptan use and no historical discontinued triptans; no current triptan use and no historical discontinued triptans (triptan-naïve); and history of =1, ≥1 and ≥2 discontinued triptans. Triptan failure was defined as discontinuation of any triptan, for any reason, including insufficient response and/or tolerability.
Results
The proportion of participants with ≥1 on-treatment adverse event (AE) was 57.6–66.3% across triptan subgroups. Rimegepant-related AEs (17.7–23.2%), treatment discontinuations (1.6–3.8%) and the most common AE (upper respiratory tract infection, 7.7–9.5%) were consistent across subgroups. After long-term treatment, the proportion of participants who preferred rimegepant to their previous medication was >75% in all triptan subgroups.
Conclusions
Long-term acute treatment of migraine with rimegepant 75 mg up to once daily was safe and well tolerated in triptan-naïve participants, current triptan users and those with single or multiple historical triptan discontinuations. Trial Registration NCT03266588.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Georgetown Headache Center, Medstar Georgetown University Hospital, Washington, DC, USA.
- Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.
- US Medical Affairs, Pfizer Inc., Groton, CT, USA.
ORCID-Profile: Jessica Ailani
Förderung
- Pfizer
Zitieren
APA
Ailani, J., Pavlovic, J., Pixton, G. C., & Fullerton, T. (2025). Rimegepant safety and patient-reported outcomes among triptan-naïve, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study. Cephalalgia. https://doi.org/10.1177/03331024251343309
Vancouver
Ailani J, Pavlovic J, Pixton GC, Fullerton T. Rimegepant safety and patient-reported outcomes among triptan-naïve, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study. Cephalalgia. 2025. doi:10.1177/03331024251343309
BibTeX
@article{Ailani2025,
author = {Ailani, Jessica and Pavlovic, Jelena and Pixton, Glenn C and Fullerton, Terence},
title = {Rimegepant safety and patient-reported outcomes among triptan-naïve, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study},
journal = {Cephalalgia},
year = {2025},
doi = {10.1177/03331024251343309}
}
EUVIMED